KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Accumulated Depreciation & Amortization (2020 - 2025)

AbCellera Biologics' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $16.0 million for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Depreciation & Amortization fell 56.53% year-over-year to $16.0 million, compared with a TTM value of $16.0 million through Sep 2025, down 56.53%, and an annual FY2024 reading of $39.7 million, up 62.81% over the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $16.0 million at AbCellera Biologics, up from $10.8 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $39.7 million in Q4 2024, with the low at $4.8 million in Q1 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $17.7 million, with a median of $14.5 million recorded in 2021.
  • Year-over-year, Accumulated Depreciation & Amortization surged 158.7% in 2021 and then tumbled 70.43% in 2025.
  • Tracing ABCL's Accumulated Depreciation & Amortization over 5 years: stood at $14.5 million in 2021, then soared by 92.67% to $27.8 million in 2022, then fell by 12.38% to $24.4 million in 2023, then skyrocketed by 62.81% to $39.7 million in 2024, then crashed by 59.6% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Accumulated Depreciation & Amortization are $16.0 million (Q3 2025), $10.8 million (Q2 2025), and $5.3 million (Q1 2025).